SOUTH SAN FRANCISCO, Calif. — August 7, 2025 — Leads & Copy — Alector, Inc. (Nasdaq: ALEC) reported its second quarter 2025 financial results and provided recent portfolio and business updates. The company’s cash, cash equivalents, and investments totaled $307.3 million as of June 30, 2025.
Topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN is expected by mid-Q4 2025. The ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer’s disease is expected to complete in 2026. Alector is continuing to progress its Alector Brain Carrier programs, including its anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA. The company’s cash, cash equivalents, and investments of $307.3 million provide runway into the second half of 2027.
According to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector, the topline results from the INFRONT-3 Phase 3 trial of latozinemab represent a key inflection point for Alector and for the FTD community. Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development at Alector, added that the company has made steady progress across its wholly owned preclinical and research pipeline, including programs powered by its proprietary Alector Brain Carrier platform.
Recent Clinical Updates include:
Alector and GSK remain on track to report topline data by the middle of the fourth quarter of 2025 from the pivotal INFRONT-3 Phase 3 trial evaluating latozinemab in frontotemporal dementia due to a GRN gene mutation (FTD-GRN). The SAP will include plasma progranulin (PGRN) as a co-primary endpoint along with the Clinical Dementia Rating® plus National Alzheimer’s Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB).
The global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in early Alzheimer’s disease (AD) is ongoing, with enrollment completed in April 2025 and trial completion expected in 2026.
Alector continues to advance its preclinical and early research pipeline, selectively supported by Alector Brain Carrier (ABC), the company’s proprietary blood-brain barrier technology platform.
Neil Berkley, M.B.A., assumed the role of Interim Chief Financial Officer in June 2025 while continuing as Chief Business Officer. In the third quarter of 2025, the U.S. Patent and Trademark Office issued a patent covering methods of treatment using latozinemab in individuals with FTD-GRN.
Second Quarter 2025 Financial Results:
Collaboration revenue for the quarter ended June 30, 2025, was $7.9 million, compared to $15.1 million for the same period in 2024. Total research and development expenses for the quarter ended June 30, 2025, were $27.6 million, compared to $46.3 million for the quarter ended June 30, 2024. Total general and administrative expenses were $14.4 million for both the three months ended June 30, 2025, and the three months ended June 30, 2024. For the quarter ended June 30, 2025, Alector reported a net loss of $30.5 million, or $0.30 per share, compared to a net loss of $38.7 million, or $0.40 net loss per share, for the same period in 2024.
Management is updating its guidance for the year ending 2025.
Katie Hogan
202-549-0557
katie.hogan@alector.com
Source: Alector
